Table 1.
Baseline characteristics (n = 90).
| Variable | NXAS (n = 30) | Zopiclone (n = 30) | Placebo (n = 30) | P-value |
|---|---|---|---|---|
| Female, n (%) | 13 (43.33) | 15(50.00) | 15 (50.00) | 0.837 |
| Age(years), mean (SD) | 59.87 (8.32) | 60.47 (9.21) | 59.10 (8.77) | 0.817 |
| Length of education (years), median (IQR)/mean (SD) | 14.00 (3.50)* | 14.87 (1.53)# | 14.00 (4.00)* | 0.526 |
| Duration of PSI (months), mean (SD) | 5.04 (2.43) | 5.50 (2.61) | 4.78 (2.76) | 0.576 |
| SIS, mean (SD) | 80.77 (2.60) | 80.67 (2.83) | 79.93 (3.17) | 0.417 |
| SAS, median (IQR) | 35.50 (9.00) | 35.00 (8.00) | 35.00 (8.00) | 0.851 |
| SDS, mean (SD) | 33.60 (5.04) | 33.70 (4.87) | 33.20 (3.64) | 0.904 |
PSI, Post-stroke insomnia. SAS, self-rating anxiety scale; SDS, self-rating depression scale;
*
median (IQR);
#
mean (SD).